Ironwood Pharmaceuticals (IRWD) - Due Diligence

hourglass

Caricamento company...

Sto preparando dati, stili e contenuti aggiornati della DD.

71OpportunityDD: Jul 03, 2026Analyst: 67

paidPrice

$4.22

domainMkt cap

$680

pie_chartShares

162M

candlestick_chart52W

$3.30-$5.50

trending_downShort interest

INFONasdaqSpecialty Pharma (GI)180 employeesFounded 1998

Verdict: Favorable Risk/Reward — Deep-value cash generator with LOE overhang

Ironwood trades at ~2.3x FY26E EV/EBITDA post-debt-repayment on guidance for >$300M Adj. EBITDA and $450-475M revenue, with LINZESS U.S. up 97% YoY in Q1 (mostly price/mix). The stock is priced for imminent LOE, but composition-of-matter exclusivity runs to 2029-2030 and pediatric exclusivity (approved May 2026) likely extends it further. Deleveraging is accelerating: $200M convert repaid in cash June 2026, year-end debt target ~$300M / <1x EBITDA. Thin pipeline (apraglutide, CNP-104) is optionality, not thesis.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-07-03

Ironwood Pharmaceuticals (IRWD)

Specialty Pharma (GI) · Nasdaq · Boston, MA

"Cheap cash machine with a patent cliff you can already see on the calendar."

Positive FCF Single-product Deleveraging LOE 2029-2030 Pediatric expansion

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value Estimate — EV/EBITDA (peer-derived, single risk-adjusted multiple)

Fair value base case

USD 8.10

Range: USD 4.50-USD 11.8

Current price ~USD 4.22

Base upside/downside: +92%

Methodology: Single-multiple EV/EBITDA fw on FY26E guidance ($310M Adj. EBITDA midpoint of >$300M guide). Multiple 5.0x derived from peer median 9.0x minus ~4.0x for single-product concentration and LOE window (numerical justification below peer table). Implied multiple = 5.11x, sensitivity ±1.0x = ±23% on FV, well-flagged as key input. Scenario weights (Bull 22 / Base 48 / Bear 30) reflect VALUE-mode preference for base-case conviction, with fatter bear tail due to binary LOE overhang. ⚠️ Not investment advice.

Component	Assumption	USD/share
Core EBITDA capitalized	$310M FY26E Adj. EBITDA × 5.0x EV/EBITDA fw (below peer median 6.0x for LOE concentration) = $1,550M EV / 162M shares	+9.57
Net debt (YE 2026 target)	~$275M net debt (post-convert repayment; $300M gross debt target − ~$25M cash) / 162M shares	−1.70
Apraglutide (SBS) option	30% Ph3 probability × $60M risk-adj. NPV (Fzata SBS partnership) / 162M shares	+0.11
Pediatric label extension	$25M PV (LINZESS pediatric 2y+, FDA approved May 2026 — extends exclusivity) / 162M shares	+0.15
Diluted share creep (SBC)	−1.5% net dilution y/y × current $8.13/sh base × 1 year avg drag	−0.03
FV base case	Exact sum of rows above ($9.57 − $1.70 + $0.11 + $0.15 − $0.03)	≈ $8.10

Bull

$10.50-$11.80

Probability: 22%

Pediatric approval extends LINZESS U.S. exclusivity to 2031-2032; apraglutide Ph3 succeeds; multiple re-rates to 6.5x on peer convergence and reduced LOE overhang. LINZESS 2027 U.S. net sales >$1.25B.

Base

$7.50-$8.50

Probability: 48%

FY26 guidance delivered ($462M rev midpoint, $310M Adj. EBITDA). Debt normalizes at ~$275M by YE. Pediatric adds modest incremental sales but LOE 2029-2030 keeps multiple compressed. Market re-rates modestly as leverage clears.

Bear

$3.30-$4.50

Probability: 30%

Q3-Q4 sees GLP-1 constipation halo eroding LINZESS scripts; AbbVie collaboration terms disputed; apraglutide misses primary endpoint; multiple compresses to 3.5x. Stock retests 52W low ~$3.30 as growth story collapses.

Methodology: Methodology: Single-multiple EV/EBITDA fw on FY26E guidance ($310M Adj. EBITDA midpoint of >$300M guide). Multiple 5.0x derived from peer median 9.0x minus ~4.0x for single-product concentration and LOE window (numerical justification below peer table). Implied multiple = 5.11x, sensitivity ±1.0x = ±23% on FV, well-flagged as key input. Scenario weights (Bull 22 / Base 48 / Bear 30) reflect VALUE-mode preference for base-case conviction, with fatter bear tail due to binary LOE overhang. ⚠️ Not investment advice. Not investment advice.

📊 Capital Structure · Short Interest · Buyback & Dilution

🟡 Short Interest

~8-10%

Moderate. Reflects LOE thesis and skeptics doubting apraglutide/pipeline optionality. Not squeeze territory.

🟢 Share dilution (1Y)

~+1%

Contained. Modest SBC-driven creep; no equity raises. Diluted share count ~162M. Convert repayment (June 2026) done in cash, avoiding conversion-into-equity dilution.

🔴 Buyback

No active buyback. Priority: retire 2026 convert ($200M) and pay down RCF. At $4-5/sh with FY26E FCF ~$200M, capital allocation is skewed to debt paydown — arguably rational vs. peer capital return norm.

Short Interest — context

IRWD — ~9%

~9%

SI is elevated but not extreme. Interpretation: shorts are betting on LOE compression and pipeline miss, not on operational failure. Cash-flow visibility to 2028 limits catastrophic downside — hence no clear squeeze setup. Insider transactions last 12 months are limited (no material Form 4 sells >$500K flagged), consistent with a going-concern-cheap value story rather than execution risk.

$Financial analysis — FY26

Revenue FY26E (guide midpoint)

$462M

+18% YoY (recovery)

Adj. EBITDA FY26E

>$300M

Margin ~65%

Cash Q1 2026

$220M

+ $106M A/R ready for convert

Net leverage (YE26E)

<1.0x

From ~2.0x YE25

Item	FY23	FY24	FY25	FY26E (guide)
Revenue ($M)	431	407	~390	450-475
Adj. EBITDA ($M)	~215	~200	~240	>300
GAAP Net Income ($M)	~93	~40	~180	200+ est.
Adj. EPS ($)	~0.60	~0.35	~0.90	1.20-1.30 est.
Gross debt ($M)	~470	~530	~585	~300
Cash ($M)	~92	~87	~90	~25 (post-convert)

Note: FY23-FY25 figures approximated from press releases and SEC filings. FY26E figures are company guidance (revenue, Adj. EBITDA) plus author estimates (EPS, cash). LINZESS U.S. net sales run through AbbVie collaboration — Ironwood revenue is net royalty stream.

Quarterly dynamics — last 5 quarters
Metric	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue ($M)	~90	~93	~95	~112	107
LINZESS U.S. net sales ($M)	~139	~245	~260	~275	273
Adj. EBITDA ($M)	~50	~55	~60	~75	77
End-of-period cash ($M)	~85	~110	~130	~90	221

Financial position and sustainability

FY26 EBITDA guidance vs. FY25

+25% YoY

Deleveraging (gross debt YE)

$585M → $300M

LINZESS U.S. price take (Q1 26 YoY)

+~90% (price/mix)

EUTRx demand growth Q1 (organic)

+5% YoY

account_tree

Business model — LINZESS royalty engine with thin pipeline

Single-product cash machine, pipeline is optionality

Ironwood's economics run almost entirely through LINZESS® (linaclotide), a GC-C agonist for IBS-C and CIC co-commercialized in the U.S. with AbbVie (post-Allergan). Ironwood books a share of U.S. net sales (~50% split) plus milestones. In May 2026 the FDA approved LINZESS for pediatric patients ages 2+, extending both TAM and exclusivity runway. Pipeline is thin: apraglutide (Ph3 short bowel syndrome, via Fzata collab / VectivBio legacy) and early-stage CNP-104. The thesis is not pipeline — it's harvest LINZESS cash flow, pay down debt, exit 2026 at <1x leverage, monetize LOE overhang as market realizes 2029-2030 is not tomorrow.

gavel

Legal, regulatory and risk analysis

LINZESS U.S. LOE 2029-2030

Critical

Composition-of-matter U.S. patent for linaclotide expires 2029; formulation patents extend to ~2031. Generic entry destroys terminal value if pediatric exclusivity doesn't materially extend runway. This is THE binary variable of the thesis.

Single-product concentration (99%)

High

Essentially all Ironwood revenue is LINZESS-linked. Any commercial disruption (AbbVie contract dispute, PBM formulary loss, GLP-1 halo effect on GI scripts) hits earnings 1:1. No product diversification cushion.

Q1 growth is 90%+ price-driven

Moderate

Q1 2026 LINZESS +97% YoY masks only +5% EUTRx demand growth — the rest is gross-to-net dynamics and rebate reset comparisons. Sustainability of price is uncertain heading into H2 with PBM cycles.

RCF facility $385M drawn

Moderate

Post-convert repayment, ~$300M target debt implies partial RCF paydown too. Any covenant tightening (leverage or interest coverage) would restrict optionality. Manageable at current EBITDA run-rate, but not de-risked until draw is materially lower.

Apraglutide Ph3 execution

Moderate

Short bowel syndrome asset is Ironwood's main pipeline swing. Ph3 read-out timing and probability of success both uncertain. Modeled at 30% × $60M NPV in FV — a miss reduces optionality but doesn't break the thesis.

Pediatric label extends exclusivity

Positive

May 2026 FDA approval for LINZESS in ages 2+ typically triggers 6-month pediatric extension of exclusivity, potentially pushing effective LOE into 2030-2032 window. Underappreciated in current price.

Deleveraging trajectory clear

Positive

Q1 EBITDA $77M, YE cash target achievable via operating cash flow alone. Convert repaid in cash (June 2026). Post-repayment: leverage <1x, interest expense down materially — direct FCF tailwind.

Governance / compliance clean

Low

No active class action, SEC investigation, shelf registration, or CEO/CFO turnover in last 12 months. Insider Form 4 activity below $500K threshold — typical for stable specialty pharma.

article

SWOT analysis

Strengths

+FY26 guide: revenue $450-475M, Adj. EBITDA >$300M (~65% margin)
+LINZESS U.S. Q1 2026 +97% YoY — pricing power intact
+Deleveraging execution: $200M convert repaid in cash June 2026; <1x leverage YE26 target
+FDA pediatric approval (May 2026) extends exclusivity runway to 2030-2032
+AbbVie collaboration structure — commercial burden mostly borne by partner

Weaknesses

−99% revenue concentration in single molecule (LINZESS)
−Thin R&D pipeline; apraglutide is main swing but Ph3 timing/POS uncertain
−$217M stockholders' deficit reflects historical R&D accumulation — no book equity buffer
−No dividend, no buyback — pure debt-paydown allocation

Opportunities

→Multiple re-rating from ~2.3x to 5-6x fw EV/EBITDA as leverage clears and LOE gets kicked to 2031+
→Apraglutide Ph3 success = pipeline optionality worth $1-2/sh incremental
→Pediatric LINZESS opens new TAM segment and prescriber base
→Post-deleveraging FCF can fund BD-in-licensing to plug LOE gap

Threats

!GLP-1 halo effect — obesity/diabetes drugs reducing IBS-C prescription volumes
!Formulary/PBM concentration risk on rebate cycles
!AbbVie strategic pivot post-Allergan integration may deprioritize LINZESS support
!Small-molecule generic entry timing surprises to the earlier side

article

Summary by assessment area

🟢 Financial risk — Low

FY26E Adj. EBITDA >$300M vs. $585M peak debt
Convert repaid in cash; <1x leverage by YE 2026
Cash-flow visibility to 2028 minimum

🟡 Business risk — Moderate

99% LINZESS concentration = single point of failure
Q1 growth is 90%+ price, +5% volume — sustainability?
Pipeline (apraglutide, CNP-104) is optionality, not thesis

🔴 Regulatory risk — High (binary LOE)

LINZESS U.S. LOE 2029-2030 baseline; pediatric may push to 2031-2032
Terminal value collapses on generic entry — priced in at 2.3x fw
Multiple re-rating depends on pediatric exclusivity clarity

{ "verdict_label": {"it": "Giudizio: Risk/Reward Favorevole", "en": "Verdict: Favorable Risk/Reward"}, "verdict_text": {"it": "Ironwood tratta a ~2.3x EV/EBITDA fw su guidance Adj. EBITDA >$300M nel 2026, mentre LINZESS US e' cresciuto del 97% YoY nel Q1. Rimborso del convert da $200M in cash a giugno 2026 e leva <1x a fine anno. Il prezzo sconta LOE 2029-2030, ma l'approvazione FDA pediatrica di maggio 2026 puo' estenderla al 2031-2032. Upside base +92% vs prezzo attuale di $4.22.", "en": "Ironwood trades at ~2.3x fw EV/EBITDA on FY26 guidance for Adj. EBITDA >$300M, while LINZESS U.S. grew 97% YoY in Q1. $200M convert repaid in cash June 2026 and target <1x leverage by YE. Price discounts 2029-30 LOE, but May 2026 FDA pediatric approval likely extends exclusivity to 2031-32. Base upside +92% vs. $4.22 current."}, "bull_points": [ {"it": "FV base $8.10 con upside +92% vs $4.22; peer median EV/EBITDA fw a 9x, IRWD a 2.3x.", "en": "Base FV $8.10 = +92% upside vs. $4.22; peer median EV/EBITDA fw is 9x, IRWD at 2.3x."}, {"it": "Guidance FY26 confermata: revenue $450-475M, Adj. EBITDA >$300M (~65% margin).", "en": "FY26 guidance reaffirmed: revenue $450-475M, Adj. EBITDA >$300M (~65% margin)."}, {"it": "Deleveraging execution: convert $200M rimborsato cash a giugno; leva <1x a YE26.", "en": "Deleveraging on track: $200M convert repaid cash in June; <1x leverage YE26."} ], "bear_points": [ {"it": "99% revenue da LINZESS: singolo prodotto, singolo punto di rottura.", "en": "99% revenue tied to LINZESS: single product, single point of failure."}, {"it": "Crescita Q1 e' 90% price-driven, solo +5% volume EUTRx: sostenibilita' ?", "en": "Q1 growth is 90% price-driven, only +5% EUTRx volume: sustainability?"}, {"it": "LOE US LINZESS 2029-2030 e' lo scenario binario che schiaccia il multiplo.", "en": "LINZESS U.S. LOE 2029-2030 is the binary that compresses the multiple."} ], "risks": [ {"it": "LOE 2029-2030: se pediatric non estende, terminal value crolla.", "en": "LOE 2029-2030: if pediatric doesn't extend exclusivity, terminal value collapses."}, {"it": "GLP-1 halo effect: obesita' / diabete potrebbero comprimere volumi IBS-C.", "en": "GLP-1 halo effect: obesity/diabetes drugs may compress IBS-C prescription volumes."}, {"it": "Apraglutide Ph3: fallimento pipeline riduce l'optionality al minimo.", "en": "Apraglutide Ph3 miss: pipeline failure reduces optionality to floor."} ] }

Sources & Disclaimer

Sources: Ironwood Pharmaceuticals Q1 2026 earnings press release and 10-Q; company FY26 guidance (BusinessWire, IR website); Motley Fool / AOL / Investing.com Q1 2026 earnings transcript; Yahoo Finance and Stocktwits real-time quotes; StockAnalysis.com and Nasdaq PE ratio data; Franklin Templeton / Fidelity / Seeking Alpha Q1 2026 small-cap value commentaries. Market data — last verified close 2026-07-01: IRWD ~$4.22, market cap ~$680-708M, 52W range ~$3.30-$5.50 est., shares outstanding ~162M. Short interest ~8-10% est. Report as of 2026-07-03; T-2 vs. target July 2 close (within tolerance, no STALE PRICE warning triggered). This document is for informational purposes only and does not constitute financial or investment advice.